Cargando…
A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
The widespread use of immune checkpoint inhibitors in several malignancies has revealed new immune-related adverse events. Bullous pemphigoid (BP) is an antibody-driven autoimmune disease characterized by skin inflammation and fluid-filled bullae. Herein, a 69-year-old man with lung squamous cell ca...
Autores principales: | Guan, Shasha, Zhang, Linlin, Zhang, Junyan, Song, Wenjing, Zhong, Diansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845947/ https://www.ncbi.nlm.nih.gov/pubmed/36685586 http://dx.doi.org/10.3389/fimmu.2022.1068978 |
Ejemplares similares
-
Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid
por: Zhou, Tong, et al.
Publicado: (2021) -
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
por: Mari, Roxane, et al.
Publicado: (2022) -
Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study
por: Schauer, Franziska, et al.
Publicado: (2022) -
Effect of early initiation of steroid-sparing drugs in patients with bullous pemphigoid
por: Fenne, Inger Johanne, et al.
Publicado: (2023) -
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
por: Sadik, Christian D., et al.
Publicado: (2021)